The VLAN design places the regulated pharmaceutical lab systems on the same segment (VLAN 200, 10.2.0.0/22) as general user traffic, meaning there is no security zone boundary between a highly-sensitive, validated/GxP environment and an untrusted user population. In a security-zone model, this is precisely a zone traversal weakness: any host or user in the general-purpose zone can reach the regulated zone directly because no conduit or enforcement point separates them, so it is the design flaw the consultant should prioritize before the facility goes live. Lateral movement describes an attacker pivoting between already-compromised hosts after gaining a foothold, which presupposes the segmentation problem rather than being the root architectural gap identified in the plan review.
Community Discussion